| scholarly article | Q13442814 |
| P50 | author | Helmut Jonuleit | Q30511642 |
| P2093 | author name string | P P Lee | |
| J Knop | |||
| G Schuler | |||
| T Tüting | |||
| A H Enk | |||
| A Giesecke-Tuettenberg | |||
| A Kandemir | |||
| B Thurner-Schuler | |||
| L Paragnik | |||
| T B Stuge | |||
| P2860 | cites work | Dendritic cells and the control of immunity | Q27860918 |
| Phenotypic analysis of antigen-specific T lymphocytes | Q28290058 | ||
| Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor | Q29619247 | ||
| Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application | Q33536357 | ||
| Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. | Q33855405 | ||
| Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. | Q35834680 | ||
| Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells | Q36350884 | ||
| Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity | Q36366051 | ||
| Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines | Q36366108 | ||
| CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha | Q36367113 | ||
| Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma | Q36375683 | ||
| Origin, maturation and antigen presenting function of dendritic cells. | Q40906220 | ||
| Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo | Q41079157 | ||
| Dendritic cells as adjuvants for immune-mediated resistance to tumors | Q41649620 | ||
| Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients | Q41672999 | ||
| Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells | Q42944333 | ||
| High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals | Q42947076 | ||
| Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells | Q46578425 | ||
| Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. | Q54451826 | ||
| Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells | Q57275942 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dendritic cell | Q506253 |
| P304 | page(s) | 243-251 | |
| P577 | publication date | 2001-07-01 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. | |
| P478 | volume | 93 |
| Q46269868 | A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. |
| Q53303142 | A closed and single-use system for monocyte enrichment: potential for dendritic cell generation for clinical applications. |
| Q31031447 | A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells |
| Q37002959 | A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients |
| Q39338676 | A novel and simple method for generation of human dendritic cells from unfractionated peripheral blood mononuclear cells within 2 days: its application for induction of HIV-1-reactive CD4(+) T cells in the hu-PBL SCID mice |
| Q35621559 | A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. |
| Q82853651 | A role for CD4+CD25+ T cells in regulation of the immune response during human tuberculosis |
| Q44776861 | Activated human dendritic cells express inducible cyclo-oxygenase and synthesize prostaglandin E2 but not prostaglandin D2. |
| Q47841318 | Addition of interferon-alpha to a standard maturation cocktail induces CD38 up-regulation and increases dendritic cell function. |
| Q45010454 | Allogeneic tumor-dendritic cell fusion vaccines for generation of broad prostate cancer T-cell responses |
| Q44473359 | Antigen loading of dendritic cells with whole tumor cell preparations |
| Q30310231 | Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy |
| Q36546862 | Augmentation of autologous T cell reactivity with acute myeloid leukemia (AML) blasts by Toll-like receptor (TLR) agonists |
| Q44437073 | Autologous dendritic cell based adoptive immunotherapy of patients with colorectal cancer-A phase I-II study |
| Q36509697 | Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells |
| Q81797197 | Biodistribution of radiolabelled human dendritic cells injected by various routes |
| Q60127514 | CD11c MHCII GM-CSF-bone marrow-derived dendritic cells act as antigen donor cells and as antigen presenting cells in neoepitope-elicited tumor immunity against a mouse fibrosarcoma |
| Q35216462 | Can tolerogenic dendritic cells help to modulate allo-immune responses in the setting of hematopoietic cell transplantation? |
| Q33519806 | Canine CXCL7 and its functional expression in dendritic cells undergoing maturation |
| Q56999847 | Characterization of Monocyte-Derived Dendritic Cells Maturated With IFN-alpha |
| Q36766798 | Chemokines as novel and versatile reagents for flow cytometry and cell sorting |
| Q38094811 | Clinical trials in cellular immunotherapy for brain/CNS tumors |
| Q40390484 | Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination |
| Q61698866 | Comparison of α-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients |
| Q40365927 | Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma |
| Q38097034 | Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells |
| Q28085724 | Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines |
| Q80581822 | Cytokine profiles of canine monocyte-derived dendritic cells as a function of lipopolysaccharide- or tumor necrosis factor-alpha-induced maturation |
| Q36256389 | DNA is an efficient booster of dendritic cell-based vaccine |
| Q58409682 | Dendritic Cell-Based Immunotherapy |
| Q33886261 | Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis |
| Q36262281 | Dendritic cell dysfunction in cancer: a mechanism for immunosuppression |
| Q38069183 | Dendritic cell immunotherapy in ovarian cancer |
| Q35762464 | Dendritic cell immunotherapy: mapping the way. |
| Q34482055 | Dendritic cell maturation in active immunotherapy strategies. |
| Q37773266 | Dendritic cell preparation for immunotherapeutic interventions. |
| Q38059518 | Dendritic cell therapy for Type 1 diabetes suppression |
| Q36899104 | Dendritic cell vaccination |
| Q37628701 | Dendritic cell vaccination as a treatment modality for melanoma |
| Q38850950 | Dendritic cell vaccination in melanoma patients: From promising results to future perspectives |
| Q35114583 | Dendritic cell vaccination: new hope for the treatment of metastasized endocrine malignancies |
| Q35922426 | Dendritic cell-based immunotherapy of malignant gliomas |
| Q36752195 | Dendritic cell-based immunotherapy of malignant melanoma: success and limitations |
| Q36436168 | Dendritic cell-based tumor vaccines and antigen presentation attenuators |
| Q36642308 | Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial |
| Q34661797 | Dendritic cell-based vaccines: barriers and opportunities |
| Q35169134 | Dendritic cells and immunotherapy for cancer |
| Q36085614 | Dendritic cells as therapeutic vaccines against cancer |
| Q36899314 | Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products |
| Q79967042 | Dendritic cells in cancer immunotherapy |
| Q85052740 | Dendritic cells in cancer immunotherapy |
| Q36115652 | Dendritic cells in melanoma immunotherapy |
| Q34983449 | Dendritic cells: making progress with tumour regression? |
| Q36284556 | Dendritic cells: tools and targets for antitumor vaccination |
| Q36939901 | Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting |
| Q35053382 | Determinant spreading and tumor responses after peptide-based cancer immunotherapy |
| Q37960189 | Developing dendritic cell-based therapies to condition immune responses to novel oncogenic proteins and stem cells |
| Q26752558 | Direct Delivery of Antigens to Dendritic Cells via Antibodies Specific for Endocytic Receptors as a Promising Strategy for Future Therapies |
| Q36371068 | Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma |
| Q24796652 | Diversity and recognition efficiency of T cell responses to cancer |
| Q34658123 | Effect of ex vivo culture duration on phenotype and cytokine production by mature dendritic cells derived from peripheral blood monocytes |
| Q39669149 | Enhanced cytotoxicity of IL-24 gene-modified dendritic cells co-cultured with cytokine-induced killer cells to hepatocellular carcinoma cells |
| Q36038020 | Enhancement of the Immunostimulatory Functions of Ex Vivo-Generated Dendritic Cells from Early-Stage Colon Cancer Patients by Consecutive Exposure to Low Doses of Sequential-Kinetic-Activated IL-4 and IL-12. A Preliminary Study |
| Q39298181 | Epitope diversification driven by non-tumor epitope-specific Th1 and Th17 mediates potent antitumor reactivity |
| Q24799742 | Evaluation of in vivo labelled dendritic cell migration in cancer patients |
| Q36959680 | Exploiting dendritic cells for active immunotherapy of cancer and chronic infections |
| Q35673900 | Gene therapy for cancer: present status and future perspective |
| Q35039002 | Gene-modified dendritic cells for immunotherapy against cancer |
| Q37173478 | Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs. |
| Q35765914 | Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. |
| Q37980404 | Harnessing human plasmacytoid dendritic cells as professional APCs. |
| Q34627677 | Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination |
| Q43872509 | Human monocyte-derived dendritic cells are deficient in prostaglandin E2 production |
| Q79084860 | Immature dendritic cell/tumor cell fusions induce potent antitumour immunity |
| Q36517706 | Immune cell recruitment and cell-based system for cancer therapy |
| Q81308391 | Immune characterization of clinical grade-dendritic cells generated from cancer patients and genetically modified by an ALVAC vector carrying MAGE minigenes |
| Q46612829 | Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia. |
| Q30440584 | Immunity to melanoma antigens: from self-tolerance to immunotherapy |
| Q36116566 | Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells |
| Q37718447 | Immunogenicity of targeted lentivectors. |
| Q36239661 | Immunotherapy for gynaecological malignancies. |
| Q36453216 | Immunotherapy for melanoma: current status and perspectives |
| Q36206601 | Immunotherapy in multiple myeloma--possibility or probability? |
| Q35142329 | Immunotherapy of cancer by active vaccination: does allogeneic bone marrow transplantation after non-myeloablative conditioning provide a new option? |
| Q39232484 | Immunotherapy of malignant melanoma with tumor lysate-pulsed autologous monocyte-derived dendritic cells |
| Q57732968 | Immunotherapy of malignant melanoma – Basic principles and novel therapeutic approaches |
| Q36689152 | Immunotherapy of multiple myeloma: the start of a long and tortuous journey |
| Q40438301 | Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells |
| Q37086013 | Immunotherapy opportunities in ovarian cancer. |
| Q24651090 | Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients |
| Q35440540 | Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. |
| Q84529622 | Interleukin-4 enhances trafficking and functional activities of GM-CSF-stimulated mouse myeloid-derived dendritic cells at late differentiation stage |
| Q34269134 | Intranodal Administration of Peptide-Pulsed Mature Dendritic Cell Vaccines Results in Superior CD8+T-Cell Function in Melanoma Patients |
| Q41967129 | Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients |
| Q40360053 | Intraoperative subcutaneous or intrasplenic vaccination with modified autologous tumor cells leads to enhanced survival in a mouse tumor model. |
| Q33811417 | Investigation of immunological approaches to enhance engraftment in a 1 Gy TBI canine hematopoietic stem cell transplantation model |
| Q40886985 | Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus |
| Q74741975 | Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories |
| Q46816706 | Maturation of human monocyte-derived dendritic cells (MoDCs) in the presence of prostaglandin E2 optimizes CD4 and CD8 T cell-mediated responses to protein antigens: role of PGE2 in chemokine and cytokine expression by MoDCs |
| Q35091558 | Modulation of antitumor immune responses by hematopoietic cytokines |
| Q64094685 | Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma |
| Q43586463 | NK cells enhance the induction of CTL responses by IL-15 monocyte-derived dendritic cells. |
| Q35207632 | Novel therapeutic agents under investigation for malignant melanoma |
| Q34422110 | Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula |
| Q24793668 | Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells |
| Q79740980 | Oxymetazoline modulates proinflammatory cytokines and the T-cell stimulatory capacity of dendritic cells |
| Q38208309 | Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets. |
| Q45867029 | Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma. |
| Q35793849 | Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors |
| Q45245826 | Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination |
| Q58620001 | Phenotypic and functional characterization of mature dendritic cells from pediatric cancer patients |
| Q48356056 | Potential applications for plasmacytoid dendritic cells in cancer immunotherapy. |
| Q40057379 | Preventive and therapeutic antitumor effect of tumor vaccine composed of CpG ODN class C and irradiated tumor cells is triggered through the APCs and activation of CTLs |
| Q51050849 | Primary Human Blood Dendritic Cells for Cancer Immunotherapy-Tailoring the Immune Response by Dendritic Cell Maturation. |
| Q40672509 | Priming of T cells with Ad-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8+ T cells: implications for an efficient vaccination strategy |
| Q35922431 | Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes. |
| Q27323878 | Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. |
| Q36065947 | RNA transfer and its use in dendritic cell-based immunotherapy |
| Q36370290 | Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. |
| Q34785902 | Rational design of peptide-based tumor vaccines |
| Q36321305 | Regulatory T cells in ovarian cancer: biology and therapeutic potential |
| Q51356582 | Role of heterogeneous cell population on modulation of dendritic cell phenotype and activation of CD8 T cells for use in cell-based immunotherapies. |
| Q33433723 | Selected climatic variables and blood pressure in Central European patients with chronic renal failure on haemodialysis treatment |
| Q38101679 | T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients |
| Q37952806 | TCR-like biomolecules target peptide/MHC Class I complexes on the surface of infected and cancerous cells |
| Q57384884 | Targeting the dendritic cell: the key to immunotherapy in cancer? |
| Q37849976 | The biology of cancer testis antigens: putative function, regulation and therapeutic potential |
| Q50736412 | The first 1000 dendritic cell vaccinees. |
| Q38243215 | The graft-versus-neuroblastoma effect of allogeneic hematopoietic stem cell transplantation, a review of clinical and experimental evidence and a perspective on mechanisms |
| Q37759033 | The immunotherapeutic potential of dendritic cells in type 1 diabetes |
| Q35084257 | The use of dendritic cells in cancer immunotherapy |
| Q51799863 | Treg cells as potential cellular targets for functionalized nanoparticles in cancer therapy. |
| Q35211007 | Tumor vaccines: from gene therapy to dendritic cells--the emerging frontier |
| Q34815630 | Use of class II tetramers for identification of CD4+ T cells |
| Q37348861 | Vaccination with tumor cells pulsed with foreign peptide induces immunity to the tumor itself |
| Q38212485 | Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use? |
| Q81354727 | [Active immunotherapy of prostate cancer with a focus on dendritic cells] |
| Q79820412 | [The role of dendritic cells in immunity. Potential clinical use] |
| Q38071900 | mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic. |
Search more.